NDFIP1 limits cellular TAZ accumulation via exosomal sorting to inhibit NSCLC proliferation

Yirui Cheng, Xin Lü, Fan Li, Zhuo Chen, Yanshuang Zhang, Qing Han, Qingyu Zeng, Tingyu Wu, Ziming Li, Shun Lü, Cecilia Williams, Weiliang XiaProtein 2022 · DOI

TL;DR

This study reveals NDFIP1 as a novel tumor suppressor in non-small cell lung cancer (NSCLC) by demonstrating its role in packaging the oncogenic protein TAZ into exosomes. This exosomal sorting mechanism limits intracellular TAZ accumulation, thereby inhibiting NSCLC cell proliferation and tumor growth.

What Problem Does This Paper Address?

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality worldwide, and while targeted therapies have improved outcomes, there's a continuous need for new therapeutic targets and a deeper understanding of their mechanisms. The Hippo signaling pathway, particularly its core components YAP and TAZ, is known to drive tumor growth and is often dysregulated in cancers like NSCLC. While TAZ's oncogenic role is established, the precise mechanisms regulating its intracellular levels and its release from cells are not fully understood. Previous research indicated that NDFIP1, a known tumor suppressor in other cancers, can mediate the exosomal sorting of proteins containing WW domains. This paper investigates whether NDFIP1 interacts with TAZ (a WW domain-containing protein) and, if so, how this interaction influences TAZ's fate and NSCLC progression. The central question is: does NDFIP1 control TAZ levels by directing it into exosomes, and what are the consequences for tumor development?

Methods

The researchers employed a multi-faceted approach to investigate the role of NDFIP1 and TAZ in NSCLC:

  • Expression Analysis: They analyzed NDFIP1 mRNA and protein levels in NSCLC patient samples and cell lines using public databases (Oncomine) and experimental techniques like immunohistochemistry (IHC) and Western blotting.
  • Protein-Protein Interaction Studies: Co-immunoprecipitation (Co-IP) assays were used to confirm the direct binding between NDFIP1 and TAZ, and to investigate the specific domains involved in this interaction.
  • Exosome Isolation and Characterization: Standard ultracentrifugation methods were used to isolate exosomes from cell culture media and patient serum. These exosomes were characterized using Transmission Electron Microscopy (TEM) for morphology, Nanoparticle Tracking Analysis (NTA) for size distribution, and Western blotting to confirm the presence of exosomal markers and cargo proteins like TAZ.
  • Functional Assays (In Vitro):
    • Cell Proliferation Assays: Cell Counting Kit-8 (CCK-8) was used to measure cell viability and proliferation rates in cells with altered NDFIP1 or TAZ levels.
  • Protein Degradation Studies: Cycloheximide (CHX) chase experiments were performed to assess the degradation rates of TAZ in the presence or absence of NDFIP1.
  • Subcellular Localization: Nuclear and cytoplasmic fractions were isolated to determine the distribution of TAZ within the cell.
  • Inhibitor Studies: Proteasome (MG132) and lysosome (CQ) inhibitors were used to explore the role of these degradation pathways. Exosome secretion inhibitors (GW4869) and related gene knockdown (RAB27B) were employed to investigate the role of exosome secretion.
  • Functional Assays (In Vivo):
    • Xenograft Models: NSCLC cells with manipulated NDFIP1 expression were implanted into immunodeficient mice to assess tumor growth, size, and weight.
  • Immunohistochemistry (IHC): Proliferation markers (PCNA, Ki-67) were analyzed in tumor tissues from xenograft models.
  • Clinical Correlation: TAZ and NDFIP1 expression levels were correlated in NSCLC patient samples, and exosomal TAZ levels were compared between healthy individuals and NSCLC patients.

Datasets

  • Public Databases: Oncomine database was used for analyzing NDFIP1 mRNA expression and copy number variations in NSCLC. Kaplan-Meier Plotter was used for survival analysis.
  • Clinical Samples: 17 pairs of NSCLC tumor and paratumor tissue samples were collected. 61 blood samples (25 from normal donors and 36 from NSCLC patients) were collected for serum exosome analysis.
  • Cell Lines: Various NSCLC cell lines (A549, SPC-A1, SPC-A1-BM, H520, HCC95, H2170) and a normal bronchial epithelial cell line (Beas-2B) were used. HEK-293T cells were used for lentivirus packaging.

Key Insights and Ideas

  • NDFIP1 as a TAZ "Gatekeeper": The most striking insight is that NDFIP1 acts as a crucial regulator of TAZ by actively sorting it into exosomes. This suggests that cells use exosomal secretion as a mechanism to control the levels of oncogenic proteins like TAZ.
  • Exosomal Sorting is NDFIP1-Dependent: The presence of TAZ in exosomes is not a passive process; it specifically requires NDFIP1. This highlights NDFIP1's active role in the exosome biogenesis and cargo selection pathway.
  • NDFIP1's Dual Role in TAZ Regulation: NDFIP1's action leads to decreased intracellular TAZ (by exporting it) and increased exosomal TAZ. This dual effect is key to its tumor-suppressive function.
  • TAZ Accumulation Drives Proliferation: When NDFIP1 is low (as seen in NSCLC), TAZ accumulates intracellularly, leading to increased cell proliferation and tumor growth. This directly links NDFIP1's absence to a pro-tumorigenic state.
  • Clinical Relevance: The findings are supported by clinical data showing low NDFIP1 and high intracellular TAZ in NSCLC patients, and importantly, lower exosomal TAZ in the serum of NSCLC patients, suggesting potential diagnostic utility.

Key Results

  • NDFIP1 is Downregulated in NSCLC: NDFIP1 expression (mRNA and protein) was significantly lower in NSCLC tissues and cell lines compared to normal counterparts. Lower NDFIP1 levels correlated with shorter overall survival (OS) and progression-free survival (PFS).
  • NDFIP1 Interacts with TAZ: Co-IP assays confirmed a direct interaction between NDFIP1 and TAZ, specifically requiring TAZ's WW domain.
  • TAZ is Packaged into Exosomes via NDFIP1: TAZ was found to be enriched in exosomes, and this process was dependent on NDFIP1. Knockout of NDFIP1 reduced TAZ in exosomes, while its overexpression increased it.
  • NDFIP1 Controls Intracellular TAZ Levels: Knockdown of NDFIP1 led to a significant increase in cellular TAZ protein levels, without affecting TAZ mRNA or its degradation rate. Conversely, NDFIP1 overexpression reduced cellular TAZ.
  • NDFIP1 Inhibits NSCLC Proliferation: NDFIP1 knockout/knockdown promoted NSCLC cell proliferation and tumor growth in vitro and in vivo. This effect was abolished when TAZ was silenced, indicating TAZ is the downstream mediator.
  • Clinical Correlation: A negative correlation was observed between NDFIP1 and intracellular TAZ levels in NSCLC patient samples. Conversely, serum exosomal TAZ levels were lower in NSCLC patients compared to healthy controls.

Limitations and Future Work

  • YAP vs. TAZ Specificity: While NDFIP1 interacts with TAZ, it showed minimal interaction with YAP. The paper notes that the WW domain-PPxY interaction can be complex, and further research is needed to fully explain this differential interaction.
  • Mechanism of TAZ Recognition: The study confirms NDFIP1 recognizes TAZ via its WW domain, but the precise molecular details of this recognition and subsequent sorting into exosomes could be further elucidated.
  • Broader Clinical Validation: While clinical samples were analyzed, the authors suggest that a larger sample size is needed for definitive validation of serum exosomal TAZ as a diagnostic biomarker.
  • Therapeutic Potential: The findings suggest NDFIP1 as a potential therapeutic target or a biomarker for NSCLC. Future work could explore strategies to restore NDFIP1 function or modulate TAZ exosomal export for therapeutic benefit.
  • Exosome Biogenesis Details: While NDFIP1's role in exosomal sorting is shown, a deeper dive into the specific ESCRT machinery or other pathways involved in NDFIP1-mediated TAZ packaging could be beneficial.

Summary updated

Abstract

NDFIP1 has been previously reported as a tumor suppressor in multiple solid tumors, but the function of NDFIP1 in NSCLC and the underlying mechanism are still unknown. Besides, the WW domain containing proteins can be recognized by NDFIP1, resulted in the loading of the target proteins into exosomes. However, whether WW domain-containing transcription regulator 1 (WWTR1, also known as TAZ) can be packaged into exosomes by NDFIP1 and if so, whether the release of this oncogenic protein via exosomes has an effect on tumor development has not been investigated to any extent. Here, we first found that NDFIP1 was low expressed in NSCLC samples and cell lines, which is associated with shorter OS. Then, we confirmed the interaction between TAZ and NDFIP1, and the existence of TAZ in exosomes, which requires NDFIP1. Critically, knockout of NDFIP1 led to TAZ accumulation with no change in its mRNA level and degradation rate. And the cellular TAZ level could be altered by exosome secretion. Furthermore, NDFIP1 inhibited proliferation in vitro and in vivo, and silencing TAZ eliminated the increase of proliferation caused by NDFIP1 knockout. Moreover, TAZ was negatively correlated with NDFIP1 in subcutaneous xenograft model and clinical samples, and the serum exosomal TAZ level was lower in NSCLC patients. In summary, our data uncover a new tumor suppressor, NDFIP1 in NSCLC, and a new exosome-related regulatory mechanism of TAZ.
BibTeX
@inproceedings{cheng2022ndfip,
  author = {Yirui Cheng and Xin Lü and Fan Li and Zhuo Chen and Yanshuang Zhang and Qing Han and Qingyu Zeng and Tingyu Wu and Ziming Li and Shun Lü and Cecilia Williams and Weiliang Xia},
  title = {{NDFIP1 limits cellular TAZ accumulation via exosomal sorting to inhibit NSCLC proliferation}},
  booktitle = {Protein},
  year = {2022},
  doi = {10.1093/procel/pwac017},
}
Figure